Physician
Calvary Pediatrics
Calvary Pediatrics was paid $7.76M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 17% of everything it billed.
33Billing provider infoCALVARY PEDIATRICS
FAYETTEVILLE, NC 28304
FAYETTEVILLE, NC 28304
33aNPI1285999458assigned 07/12/2012
33bProvider typePediatrics Physician
28Total paid$7.76M
24GClaims396,507
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in North Carolina
Rank by total paid#53 of 433
Median peer was paid$942K
This provider vs. median8.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,992 | $617K | |
| 2019 | 26,007 | $862K | |
| 2020 | 31,248 | $869K | |
| 2021 | 62,009 | $1.31M | |
| 2022 | 87,307 | $1.38M | |
| 2023 | 87,065 | $1.58M | |
| 2024incomplete | 78,879 | $1.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 14,577 | 12,227 | $1.34M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 19,641 | 15,902 | $1.21M |
| 99199 | Unlisted special service, procedure or report | 14% | 178,705 | 105,382 | $1.08M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.8% | 7,422 | 6,448 | $686K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 8.8% | 7,693 | 6,504 | $680K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.3% | 6,253 | 5,268 | $567K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 2,768 | 2,358 | $277K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.4% | 14,086 | 11,565 | $265K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 3.4% | 9,371 | 7,970 | $260K |
| 92587 | 2.3% | 11,206 | 9,497 | $177K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.4% | 12,973 | 10,963 | $111K |
| 99460 | 1.4% | 1,667 | 1,394 | $109K |
78 more codes
| 99238 | Hospital discharge day management, 30 minutes or less | 1.2% | 1,765 | $96K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,320 | $90K |
| 99381 | 1.1% | 946 | $86K | |
| 90474 | <1% | 3,984 | $75K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,888 | $70K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,739 | $64K |
| 99462 | <1% | 1,999 | $59K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,319 | $55K |
| 92552 | <1% | 7,797 | $45K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,095 | $39K |
| 96127 | <1% | 8,359 | $33K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,413 | $31K |
| 95117 | <1% | 3,225 | $28K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 359 | $21K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 135 | $19K |
| 96161 | <1% | 5,384 | $18K | |
| 83655 | <1% | 1,492 | $18K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 283 | $15K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 53 | $13K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 393 | $13K |
| 87807 | <1% | 923 | $11K | |
| 87428 | <1% | 206 | $11K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 47 | $10K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 268 | $9K |
| 96160 | <1% | 2,113 | $7K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 228 | $7K |
| 90651 | <1% | 1,227 | $6K | |
| 85018 | <1% | 2,937 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 180 | $5K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 47 | $5K |
| 81003 | <1% | 2,595 | $4K | |
| 99221 | <1% | 43 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 359 | $3K |
| 90670 | <1% | 5,317 | $3K | |
| 90734 | <1% | 983 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 57 | $2K |
| 81025 | <1% | 350 | $2K | |
| 99051 | <1% | 59 | $1K | |
| D1206 | Topical application of fluoride varnish | <1% | 148 | $1K |
| 81005 | <1% | 993 | $847.61 | |
| 94664 | <1% | 104 | $823.69 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 335 | $790.94 |
| 90716 | <1% | 1,140 | $741.97 | |
| 87634 | <1% | 162 | $571.50 | |
| 90633 | <1% | 2,849 | $403.26 | |
| 90707 | <1% | 1,086 | $341.53 | |
| 97802 | <1% | 55 | $237.70 | |
| 90715 | <1% | 500 | $222.78 | |
| 90620 | <1% | 247 | $193.05 | |
| 90686 | <1% | 2,640 | $178.66 | |
| 90647 | <1% | 2,692 | $145.63 | |
| 99406 | <1% | 12 | $104.13 | |
| 92588 | <1% | 33 | $101.36 | |
| 94760 | <1% | 2,999 | $32.20 | |
| 99174 | <1% | 7,624 | $30.64 | |
| 90656 | <1% | 88 | $16.58 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 115 | $3.49 |
| 90723 | <1% | 2,908 | $0.12 | |
| 90681 | 0% | 3,564 | $0.00 | |
| 90700 | 0% | 915 | $0.00 | |
| 90710 | 0% | 1,042 | $0.00 | |
| 90648 | 0% | 412 | $0.00 | |
| 90461 | 0% | 174 | $0.00 | |
| 90685 | 0% | 37 | $0.00 | |
| 90655 | 0% | 66 | $0.00 | |
| 90713 | 0% | 13 | $0.00 | |
| 36416 | 0% | 1,367 | $0.00 | |
| 90696 | 0% | 976 | $0.00 | |
| 90677 | 0% | 560 | $0.00 | |
| 90697 | 0% | 1,547 | $0.00 | |
| 90680 | 0% | 394 | $0.00 | |
| 90698 | 0% | 86 | $0.00 | |
| 99441 | 0% | 22 | $0.00 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 131 | $0.00 |
| A7015 | Aerosol mask, used with dme nebulizer | 0% | 33 | $0.00 |
| 1005F | 0% | 55 | $0.00 | |
| 2016F | 0% | 83 | $0.00 | |
| A4616 | Tubing (oxygen), per foot | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialASEMOTA, LOVE (OFFICE MANAGER)